Fluidigm to Expand Sales Staff over Next Two Years | GenomeWeb

NEW YORK (GenomeWeb News) – Fluidigm intends to significantly expand its sales staff, particularly in North America, over the next two years, President and CEO Gajus Worthington told GenomeWeb Daily News this week.

"Our goal is to quadruple the size of our US sales operations over the next two years," he said. "The goal is to get the total size of that operation to 60 people.

"The reason that we're doing it is the business has expanded dramatically, even against the backdrop of the recession, and particularly in North America," said Worthington.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.